Clinical trials: Movement Abnormalities
Dyskinesias, Drug-induced
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
- Trial name
- NCT01474421
- Testing
- AQW051
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Parkinson's Disease
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- SPAN-PD™ (NCT02240030)
- Testing
- CVT-301 Low Dose, CVT-301 High Dose
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 351 people
- Sponsor
- Acorda Therapeutics
Huntington Disease
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
- Trial name
- NCT06254482
- Testing
- Votoplam
- Where
- 24 sites in Australia, Austria and 8 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease, HIV Infections
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for biomarker studies of diseases of the brain and spinal cord, that, together, are also called the central nervous system (CNS).
- Trial name
- NCT00990379
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Salena Killion
Dementia With Lewy Bodies
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
To establish the safety and efficacy of HTL0018318 compared with placebo when administered once daily for 12 weeks to patients with dementia with Lewy bodies.
- Trial name
- DLB (NCT03592862)
- Testing
- HTL0018318
- Where
- 3 sites in Japan
- Sponsor
- Nxera Pharma UK Limited
Essential Tremor
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of…
- Trial name
- NCT04032470
- Testing
- Deep Brain Stimulation Systems (DBS)
- Where
- 20 sites in Austria, Belgium and 7 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Parkinson's Disease
Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off
The purpose of this research study is to test the effect of SYN115 compared to placebo (a "sugar pill" that looks like SYN115 but does not include active drug) on movement during the "on" and "off" states as well as other…
- Trial name
- NCT01283594
- Testing
- Tozadenant (SYN115) 60 mg BID, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID
- Where
- 61 sites in United States, Argentina and 4 more
- Volunteers
- 420 people
- Sponsor
- Biotie Therapies Inc.
Parkinson Disease
The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
The study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes
- Trial name
- NCT07156773
- Testing
- XJN010 Nasal Spray
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Guangzhou Novaken Pharm Co., Ltd.
Parkinson Disease
Cartesia eXTend 3D Study
The purpose of the study is to document patient outcomes including effectiveness for Boston Scientific Corporation's Vercise Cartesia 16-contact Directional Lead(s) (X/HX) with Deep Brain Stimulation (DBS) systems for the…
- Trial name
- eXTend 3D (NCT04577651)
- Testing
- 16-contact Directional Deep Brain Stimulation
- Where
- 10 sites in Germany, Netherlands and 1 more
- Volunteers
- 58 people
- Sponsor
- Boston Scientific Corporation
Parkinson Disease
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease.
- Trial name
- NCT05036473
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Tourette's Syndrome
Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome
The purpose of this study is to evaluate the safety and efficacy of an investigational compound designated PF-03654746 compared to placebo in the treatment of adults with Tourette's Syndrome.
- Trial name
- NCT01475383
- Testing
- PF-03654746
- Where
- United States
- Sponsor
- Pfizer
Parkinson's Disease
ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease
The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRgFUS) treatment of patients with L-dopa induced dyskinesia of Parkinson's disease (LID PD).
- Trial name
- NCT02347254
- Testing
- Transcranial ExAblate
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- InSightec
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson's Disease
2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD
This study was designed to assess whether GPI 1485 has the ability to delay or stop disease progression and improve symptoms in patients with Parkinson's disease (PD) that is already being treated with a dopamine agonist therapy.
- Trial name
- NCT00209508
- Testing
- GPI 1485
- Volunteers
- 200 people
- Sponsor
- Eisai Inc.
Parkinson Disease
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
The purpose of this study is to establish safety for CEP-1347 and to determine an efficacious dose in the treatment of Parkinson's disease.
- Trial name
- NCT00040404
- Testing
- CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 806 people
- Sponsor
- Cephalon
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson Disease
Phase 1/2a Study of ANPD001 in Parkinson Disease
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease.
- Trial name
- ASPIRO (NCT06344026)
- Testing
- ANPD001, Custom Device
- Where
- 9 sites in United States
- Volunteers
- 9 people
- Sponsor
- Aspen Neuroscience
Parkinson's Disease
A Through QT/QTc Study of KW-6356
The purpose of this study is to evaluate the effects of multiple therapeutic and supratherapeutic doses of KW-6356 on the QT interval corrected for heart rate in Japanese healthy adults.
- Trial name
- NCT04342273
- Testing
- KW-6356, Moxifloxacin
- Where
- 2 sites in Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
A phase Ⅰ/Ⅱ study to evaluate the tolerability, safety, and efficacy of VGN-R09b in pa-tients with Parkinson's disease
- Trial name
- NCT06480461
- Testing
- VGN-R09b
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
Parkinson Disease
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
This trial will be a 2-part, adaptive, open label, single and/or multiple oral dose, safety, tolerability, food effect trial of CVL-751 in subjects with Parkinson's disease.
- Trial name
- NCT04295642
- Testing
- CVL-751
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cerevel Therapeutics, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.